Tri Locum Partners LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001826434

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 18 positions · Total reported value $506.14M · Top-10 concentration 80.1% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 90.9% · 3 new · 13 cut · 4 exited

Active Share (vs S&P 500): 97.4% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -1.6% · vs SPY -3.7% · Prev Value $813.22M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +2.1% · vs SPY -0.0% · Latest Value $506.14M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Tri Locum Partners LP disclosed 18 equity positions with a combined reported value of $506.14M. The filing implies a focused portfolio: its ten largest positions account for 80.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were VRTX ($69.48M), LLY ($59.03M), TEVA ($48.46M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Tri Locum Partners LP opened 3 new positions, trimmed 13 and fully exited 4, a turnover rate of 90.9% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q3 2026 were AMRX ($46.86M), CELC ($16.11M), VRDN ($1.86M).

Of the 4 positions fully exited versus the prior quarter, the largest were TARS ($20.67M), ISRG ($19.08M), CYTK ($16.53M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • AMRX AMNEAL PHARMACEUTICALS INC · $46.86M
  • CELC CELCUITY INC · $16.11M
  • VRDN VIRIDIAN THERAPEUTICS INC · $1.86M

Fully Exited (vs previous quarter)

  • TARS TARSUS PHARMACEUTICALS INC · prev qtr: $20.67M
  • ISRG INTUITIVE SURGICAL INC · prev qtr: $19.08M
  • CYTK CYTOKINETICS INC · prev qtr: $16.53M
  • BBNX BETA BIONICS INC · prev qtr: $7.73M

Insider Transactions (Form 4)

Latest Tri Locum Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Tri Locum Partners LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 19 positions worth $813.22M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-119074 (status: Approved), registered 2020-07-16
  • Regulatory AUM (Form ADV): $1.09B as of 2026-04-06
  • Client mix (by RAUM): pension and profit-sharing plans 64%, sovereign wealth funds 36%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 19 positions · $813.22M reported value (Q2 2026)
  • Top 10 holdings = 80.0% of reported value
  • Largest position: JNJ (JOHNSON & JOHNSON) at 13.3%
  • Average position size: $42.80M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 4 new, 9 added, 6 reduced, 2 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 132.90K $69.48M 13.73%
13.73%
Reduce
2 51.02K $59.03M 11.66%
11.66%
Reduce
3 1.22M $48.46M 9.57%
9.57%
Add
4 2.33M $46.86M 9.26%
9.26%
New
5 489.40K $42.23M 8.34%
8.34%
Reduce
6 160.32K $37.12M 7.33%
7.33%
Reduce
7 30.40K $29.15M 5.76%
5.76%
Reduce
8 118.38K $26.97M 5.33%
5.33%
Reduce
9 143.34K $26.43M 5.22%
5.22%
Reduce
10 73.56K $19.47M 3.85%
3.85%
Reduce
11 410.24K $18.81M 3.71%
3.71%
Reduce
12 33.00K $17.88M 3.53%
3.53%
Reduce
13 33.67K $16.97M 3.35%
3.35%
Reduce
14 202.62K $16.11M 3.18%
3.18%
New
15 177.22K $15.60M 3.08%
3.08%
Add
16 40.02K $8.21M 1.62%
1.62%
Reduce
17 144.41K $5.50M 1.09%
1.09%
Reduce
18 90.11K $1.86M 0.37%
0.37%
New

FAQ

What did Tri Locum Partners LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Tri Locum Partners LP reported 18 equity positions worth $506.14M in aggregate; its largest disclosed positions were VRTX ($69.48M), LLY ($59.03M), TEVA ($48.46M).

How large is Tri Locum Partners LP's portfolio?

Tri Locum Partners LP reported $506.14M of long equity holdings across 18 positions as of 2026-Q3. Top-10 holdings account for 80.1% of reported value.

What is Tri Locum Partners LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/tri-locum-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →